Trials / Active Not Recruiting
Active Not RecruitingNCT06212297
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
A Clinical Trial to Evaluate the Safety and Efficacy of Subretinal Re-Administration of LX101 to the Contralateral Eye in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX101 | Subretinal administration of LX101 to the contralateral, previously uninjected eye |
Timeline
- Start date
- 2023-09-12
- Primary completion
- 2025-02-06
- Completion
- 2029-03-01
- First posted
- 2024-01-18
- Last updated
- 2025-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06212297. Inclusion in this directory is not an endorsement.